Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability Todd Watanabe, president and CEO of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) sold 4,375 shares on Aug. 3, 2026, according to a recent SEC Form 4 filing.
Transaction summary Transaction value based on SEC Form 4 weighted average sale price ($26.12); post-transaction value based on Aug. 3, 2026, market close ($25.94)
Key questions – What was the motivation behind this disposition of shares? The sale was non-discretionary, executed solely to satisfy tax withholding requirements associated with the vesting of Restricted Stock Units. This type of transaction is routine and does not typically signal a shift in management’s sentiment regarding the company’s valuation or prospects. – How is the insider’s indirect ownership structured?
The ~233,000 shares held indirectly are distributed across multiple vehicles, including The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, and The Watanabe 2016 Irrevocable Trust, as well as an entity called Watanabe Ventures, LLC. Todd Watanabe disclaims beneficial ownership of these securities except to the extent of his pecuniary interest. – What is the current scale of the insider’s alignment with the company? Despite the recent sale, the insider retains a significant interest in Arcutis, holding more than 950,000 total shares.